Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study

被引：0
|
作者：
Taner Damci
Rifat Emral
Anne Louise Svendsen
Tanzer Balkir
Jiten Vora
机构：
[1] Cerrahpasa Medical School,Department of Endocrinology, Diabetes and Metabolism
[2] Istanbul University,Department of Endocrinology and Metabolic Diseases, Faculty of Medicine
[3] Ankara University,Department of Clinical, Medical, & Regulatory Affairs
[4] Ibn-i Sina Hospital,Department of Diabetes and Endocrinology
[5] Department of Biostatistics & Epidemiology,undefined
[6] Novo Nordisk Saglik Urunleri Tic. Ltd. Sti.,undefined
[7] Royal Liverpool University Hospital,undefined
[8] the SOLVE™ study group,undefined
来源：
BMC Endocrine Disorders | / 14卷
关键词：
Insulin detemir; Insulin glargine; Basal insulin; Type 2 diabetes; Weight loss; Hypoglycaemia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] COST-MINIMIZATION ANALYSIS COMPARING INSULIN GLARGINE TO INSULIN DETEMIR IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS IN BRAZIL
    Bahia, L.
    Teich, V
    VALUE IN HEALTH, 2009, 12 (07) : A506 - A506
  • [12] SURVEY ON PHYSICIAN EXPERIENCES IN INITIATION OF INSULIN IN TYPE 2 DIABETES PATIENTS: PRELIMINARY RESULTS FOR INSULIN GLARGINE
    Roussel, R.
    Almeida, O.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2013, 15 : A138 - A139
  • [13] GLYCEMIC CONTROL FOLLOWING INITIATION OF INSULIN GLARGINE OR DETEMIR IN PATIENTS WITH TYPE 2 DIABETES MELLITUS-AN ANALYSIS OF ELECTRONIC MEDICAL RECORDS
    Levin, P.
    Danel, A.
    Bromberger, L.
    Choi, J. C.
    Mersey, J.
    VALUE IN HEALTH, 2008, 11 (06) : A496 - A497
  • [14] Similar efficacy and safety with LY2963016 insulin glargine compared with insulin glargine in patients with type 2 diabetes mellitus: the ELEMENT 2 study
    Hollander, P.
    Rosenstock, J.
    Bhargava, A.
    Ilag, L. L.
    Pollom, R. K.
    Huster, W. J.
    Prince, M. J.
    DIABETOLOGIA, 2014, 57 : S388 - S388
  • [15] Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus
    Karl, D. M.
    Gill, J.
    Zhou, R.
    Riddle, M. C.
    DIABETES OBESITY & METABOLISM, 2013, 15 (07): : 622 - 628
  • [16] Observational Study of the Use of Insulin Glargine as Basal Therapy in Patients With Type 2 Diabetes Mellitus in Morocco
    Chraibi, Abdelmjid
    Iraqi, Hinde
    Seqat, Mehdi
    El Achhab, Youness
    Nejjari, Chakib
    JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2015, 5 (06) : 333 - 336
  • [17] Prospective 1 year observational study of insulin glargine initiation in 103 insulin-naive patients with type 2 diabetes
    Tadros, Labib
    Barnes, E.
    Ledger-Scott, M.
    Murphy, J.
    Jeavons, D.
    Byrne, H.
    Gray, A.
    Nayman, D.
    Pearson, S.
    DIABETES, 2007, 56 : A146 - A146
  • [18] LOWER TREATMENT COSTS WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN TYPE 1 DIABETES PATIENTS TREATED WITH A BASAL-BOLUS REGIMEN IN GERMANY
    Wiesner, T.
    Schaedlich, P. K.
    Dippel, F. W.
    Koltermann, K.
    Hagenmeyer, E. G.
    VALUE IN HEALTH, 2010, 13 (07) : A294 - A294
  • [19] Reduced nocturnal hypoglycaemia with insulin degludec as compared to insulin glargine: results of a 2-year randomised trial in type 2 diabetes
    Rodbard, H. W.
    Zinman, B.
    Cariou, B.
    Philis-Tsimikas, A.
    Handelsman, Y.
    Skjoth, T. V.
    Chu, P. -L.
    Mathieu, C.
    DIABETOLOGIA, 2012, 55 : S378 - S378
  • [20] Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
    Ilag, L. L.
    Deeg, M. A.
    Costigan, T.
    Hollander, P.
    Blevins, T. C.
    Edelman, S. V.
    Konrad, R. J.
    Ortmann, R. A.
    Pollom, R. K.
    Huster, W. J.
    Zielonka, J. S.
    Prince, M. J.
    DIABETES OBESITY & METABOLISM, 2016, 18 (02): : 159 - 168
12345